Endesa 1Q 2017 Results 09/05/2017

Size: px
Start display at page:

Download "Endesa 1Q 2017 Results 09/05/2017"

Transcription

1 Endesa 1Q 2017 Results 09/05/2017

2 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2

3 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 3

4 Stable gross margin evolution in the regulated business Liberalized business performance affected by challenging market conditions in both gas and electricity Competitive advantages from EGPE acquisition Like-for-like (1) fixed costs decreased 2% (1) Includes pension plans obligations provision update ( 12 M in 1Q 2017 and 19 M in 1Q 2016), infringement proceedings provision ( 3 M in 1Q 2016); EGPE perimeter [- 4 M of personnel and - 15 M of O&M costs] and ICT transaction [- 7 M of personnel costs and - 4 M of homogeneous perimeter in O&M] in 1Q 2017 and - 7 M on O&M costs in 1Q 2016] 4

5 Key financial figures M 1Q Q 2016 Change Like-for-like EBITDA % -19% (1) Net attributable income % -30% (2) Cash flow from operations % Change Net financial debt 5,495 (3) 4, % Exceptional market conditions in both periods affect EBITDA and Net Income comparison (1) Net of EGPE contribution in 1Q 2017 (+ 57 M) (2) Net of EGPE contribution in 1Q 2017 (+ 18 M) and 1Q 2016 (+ 4 M) (3) Gross financial debt ( 5,902 M) - Cash and cash equivalents ( 398 M) Derivatives recognized as financial assets ( 9 M) 5

6 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 6

7 Market context in 1Q 2017 Demand Electricity wholesale prices Average pool prices Spain ( /MWh) Spain (1) Endesa distribution area (2) 1Q pool price comparison in period +1.1% (Not adjusted) 7.4% 5.0% Industry +2.9% +1.3% +1.7% 1.2% Services +1.7% -2.2% -2.3% Residential +0.5% -4.6% Jan Feb Mar Jan Feb Mar 1Q Q % 71 Avg Jan-17 Feb-17 Mar % 50% increase in system thermal gap in 1Q 2017 Adjusted for weather and working days Not adjusted Demand increase driven by industry and services segments Remarkable pool price increase due to exceptional market conditions at the beginning of 1Q 2017 (1) Mainland. Source: REE (2) Mainland. Source: Endesa s own estimates 7

8 Endesa s performance in 1Q 2017 market context Energy management 15,363 Output (1) (GWh) +24% 18, ,064 2,952 3, % 6,255 8,794 Hydro -36% 8,667 Nuke +11% Unitary integrated margin: 20.4/MWh (-12% vs. 1Q 2016) (-25% l-f-l) (2) Electricity sales (1) (GWh) 25, % 25,868 4,573 4,307 1,806 1,871 4,971 5,009 3,292 3,307 11,121 11,374 1Q Q 2017 Mainland (hydro and nuke) Mainland (thermal) Non-mainland (regulated) EGPE 1Q Q 2017 Industrial SMEs Residential Portugal SCVP Challenging market scenario was partially offset by EGPE contribution (1) Energy at power plant busbars (2) Net of EGPE contribution in 1Q

9 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 9

10 Financial results M 1Q Q 2016 Change Like-f-like Revenues 5,223 4,878 7% Gross Margin 1,236 1,310-6% EBITDA % -19% EBIT % Net Financial Results (28) (51) -45% Share of profit from associates % Income tax (66) (97) -32% Net attributable income % -30% (1) (2) Net Capex % P&L evolution: (-) Negative effect of wholesale price on the liberalized business is partially offset by (+) EGPE contribution (-) D&A increase due to EGPE consolidation ( 30 M) partially offset by (+) hydro and EGPE life extension ( 16 M) (+) Net financial expenses decrease due to provisions update effect (+ 37 M change Q-o-Q) (3) (1) Net of EGPE contribution in 1Q 2017 (+ 57 M) (2) Net of EGPE contribution in 1Q 2017 (+ 18 M) and 1Q 2016 (+ 4 M) (3) Gross tangible and intangible Capex ( 241 M) - assets from clients contributions ( 33 M)) and does not include ICT investments 10

11 1Q 2017 EBITDA breakdown 1Q 2016 M 1Q 2017 % Change (%) M % EGPE: 57 Generation & Supply (1) 30% % % Generation & Supply (1) Non-mainland Gx (2) 10% % % Non-mainland Gx (2) Distribution 60% 479-6% 452 ~65% Distribution EBITDA 1Q 2016 EBITDA 1Q 2017 TOTAL % 702 TOTAL (1) Generation & Supply business EBITDA figure includes EGPE, Corporate Structure, Services and Adjustments and does not include Non-mainland generation (2) Non-mainland generation EBITDA figure includes Canary and Balearic Islands, Ceuta and Melilla 11

12 Regulated business Gross margin evolution M Non-mainland generation (1) % Distribution Q 2016 Gross Margin Dx Non-mainland Gx 1Q 2017 Gross Margin (1) Stable regulated gross margin with non-mainland Gx benefitting from previous years positive settlements (1) Non-mainland generation Gross Margin figure includes Canary and Balearic Islands, Ceuta and Melilla 12

13 Liberalized business (1) Gross margin evolution M -18% M MtM - 14 M Algerian gas 1Q 2016 Gross Margin Electricity + VAS + Other (2) Gas (underlying) Gas (MtM&Others) 1Q 2017 Gross Margin Lower unitary margin in the liberalized electricity business (with slight increase in sales volumes) GAS business EGPE contribution Tough market conditions in both electricity and gas (1) Liberalized business Gross Margin figure includes Generation and Supply business, Corporate Structure, Services and Adjustments and does not include Non-mainland generation (2) Gas business gross margin relates to that obtained in the gas supply activity 13

14 Liberalized business 1Q 2017 energy management Energy (TWh) Unitary values breakdown ( /MWh) Sales Unitary revenue Energy purchases Unitary variable cost (1) EGPE: 1.0 Mainland output Unitary margin -12% (-25% l-f-l) (3) 17.5 ex EGPE 1Q Q Q Q /MWh (+ 5.8/MWh vs 1Q 16 variable cost) Production cost (2) : 31.7/MWh (+ 2.1/MWh) Energy purchase cost: 54.5/MWh (+ 20.5/MWh) -12% electricity unitary margin ( 20.4/MWh) due to higher variable cost (1) Production cost + energy purchase costs + ancillary services (2) Production cost = fuel cost + CO 2 + taxes from Law 15/2012 (3) Net of EGPE contribution in 1Q

15 Fixed costs evolution +5% M -2% Personnel costs % O&M costs % Capitalized costs Q 2016 Reported 1Q 2016 Adjusted 1Q 2017 Adjusted 1Q 2017 Reported 2% Like-for-like (1) fixed costs reduction (1) Includes pension plans obligations provision update ( 12 M in 1Q 2017 and 19 M in 1Q 2016), infringement proceedings provision ( 3 M in 1Q 2016); EGPE perimeter [- 4 M of personnel and - 15 M of O&M costs] and ICT transaction [- 7 M of personnel costs and - 4 M of homogeneous perimeter in O&M] in 1Q 2017 and - 7 M on O&M costs in 1Q 2016] 15

16 From EBITDA to Net Income M EBITDA Depreciation and amortization EBIT Net Financial Results Associates and Others Profit before taxes 11% Taxes and minorities Net attributable Income 1Q Change (%) -12% +9% -27% -45% -55% -27% -29% -26% 16

17 Net financial debt analysis Net financial debt evolution Net debt / EBITDA ratio 1.4x 1.6x (2) M 4,938 5,495 (3) Regulatory working capital (4) ,961 5,373 Regulatory working capital (4) -23 FY 2016 Cash flow Capex+Others Di vidends FY 2016 Net debt 31/12/2016 Cash flow from operations Capex (1) ( 321 M) + Others Ordinary dividends Net debt 31/03/2017 Healthy financial leverage and strong liquidity position Endesa liquidity covers 35 months of debt maturities (1) Cash based Capex (2) Last 12 month EBITDA (3) Gross financial debt ( 5,902 M) - Cash and cash equivalents ( 398 M) Derivatives recognized as financial assets ( 9 M) (4) Mainland and non-mainland deficit 17

18 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 18

19 Robustness of regulated business Weak performance of liberalized business partially offset by clear benefits arising from EGPE acquisition Quarterly exceptional market conditions to normalize during the year 2017 targets supported by additional managerial actions º Efficiency plans will allow for like-for-like fixed costs reduction in a reflationary environment AGM approved final gross dividend against 2016 Results ( 1.333/share) A floor for 2017 gross DPS of 1.32/share is guaranteed 19

20 Appendix Endesa 1Q 2017 Results 20

21 Installed capacity and output Mainland output (1) (GWh) 12, , ,461 71% 54% 2, ,120 2,946 2,189 7,184 1,483 1Q Q 2017 Hydro CCGT +28% Domestic coal Imported coal 15,916 73% thermal output increase Nuclear EGPE Hydro and nuclear represented 54% (3) of total output (vs. 71% in 1Q 2016) GWh 1Q 2017 (and chg. vs. 1Q 2016 Total output (GWh) Total 18,980 24% Hydro 1,483-36% Nuclear 7,184 11% Coal 5,724 57% Natural gas 1,992 53% Oil-gas 1,603-1% Renewables 994 n/a Total installed capacity (GW) GW at 1Q 2017 (and chg. vs. 1Q 2016) Total Output (1) Total Installed capacity (2) Total % Hydro 4.7 0% Nuclear 3.3 0% Coal 5.3 0% Natural gas 5.4 0% Oil-gas 2.4 0% Renewables 1.7 n/a (1) Output at power plant bus bars (Gross output minus self-consumption) 21

22 S12017 S RESTO Endesa: financial debt maturity calendar Gross balance of maturities outstanding at 31 March 2017: 5,902 M (1) Bonds Bank debt and others ECPs (2) 4,223 1,287 4, , Q H Endesa's liquidity covers 35 months of debt maturities Liquidity 3,464 M 398 M in cash 3,066 M available in credit lines Average life of debt: 6.4 years (1) This gross balance includes the outstanding amounts of debt ( 5,877 M) and the mark-to-market of derivatives or fair value debt as they do not involve any cash payment (it amounted to 25 M as of ) (2) Notes issued are backed by long-term credit lines and are renewed on a regular basis. 22

23 Gross financial debt structure as of March 31 st 2017 Structure of Endesa's gross debt M 5,902 5,902 Floating 38% Euro 100% Fixed 62% By interest rate By currency Average cost of debt 2.4% 23

24 Glossary of terms (I/II) Average cost of debt (%): (cost of financial debt) / gross average financial debt Average life of debt: (principal x number of days of term) / (principal in force at 31 December x 365 days) Cash flow from operations: Net cash provided by operating activities Debt maturities coverage: maturity period (months) for vegetative debt that could be covered with the liquidity available DPS: Dividend per Share. Total gross dividend divided by number of outstanding shares as of year end. EBIT: EBITDA - Depreciation and amortization EBITDA: Revenues Purchases and Services + Work performed by the entity and capitalized Personnel expenses Other fixed operating expenses Fixed costs / Opex: Personnel expenses + Other fixed operating expenses - Work performed by the entity and capitalized Gross margin: Revenues Purchases and Services Maintenance Capex: Investment that improves the useful life of an existing capital asset Net Capex: Gross tangible and intangible Capex - assets from clients contributions subsidies Net financial debt: Gross financial debt - Cash and cash equivalents Derivatives recognized as financial assets 24

25 Glossary of terms (II/II) Net financial results: Financial Revenues - Financial Expenses + Foreign Exchanges Regulatory working capital: part of the working capital that is specifically related to the balances of CNMC settlements Revenues: Sales + Other operating revenues Unitary revenue: Revenues obtained from i) selling electricity in the liberalized market in Spain and Portugal; ii) generation ancillary services and capacity payments and iii) renewable generation incentives. All of the above divided by physical electric sales in the liberalized market in Spain and Portugal Unitary variable cost: i) fuel and CO 2 costs in ordinary regime in mainland Spain and Portugal; ii) taxes related to mainland Gx; iii) purchase energy cost to meet electricity sales in the liberalized market in Iberia; iv) ancillary services and other commercial costs related to retail sales in liberalized market in Iberia. All the above divided by physical electric sales in the liberalized market in Iberia Production cost: i) fuel and CO 2 costs in ordinary regime in mainland Spain and Portugal; ii) taxes related to mainland generation. All of them divided by mainland Spain and Portugal generation Energy purchase cost: energy cost related to energy purchases to meet electricity sales in the liberalized market in Iberia divided by energy purchases. Unitary integrated margin: Unitary revenue - Unitary variable cost VAS Business: in the context of the liberalized retail business, it is referred to energy-related products and services apart from the pure electricity or gas commodity. 25

26 Disclaimer This document contains certain "forward-looking" statements regarding anticipated financial and operating results and statistics and other future events. These statements are not guarantees of future performance and they are subject to material risks, uncertainties, changes and other factors that may be beyond ENDESA s control or may be difficult to predict. Forward-looking statements include, but are not limited to, information regarding: estimated future earnings; anticipated changes in generation and market share; expected changes in demand for gas and gas sourcing; management strategy and goals; estimated cost reductions; tariffs and pricing structure; estimated capital expenditures; estimated asset disposals; estimated changes in capacity and capacity mix; repowering of capacity and macroeconomic conditions. The main assumptions on which these expectations and targets are related to the regulatory framework, exchange rates, commodities, divestments, increases in production and installed capacity in markets where ENDESA operates, increases in demand in these markets, allocation of production amongst different technologies, increases in costs associated with higher activity that do not exceed certain limits, electricity prices not below certain levels, the cost of CCGT plants, and the availability and cost of the gas, coal, fuel oil and emission rights necessary to run our business at the desired levels. In these statements, ENDESA avails itself of the protection provided by the Private Securities Litigation Reform Act of 1995 of the United States of America with respect to forwardlooking statements. The following important factors, in addition to those discussed elsewhere in this document, could cause financial and operating results and statistics to differ materially from those expressed in our forward-looking statements: Economic and industry conditions; factors related to liquidity and financing; operating factors; strategic and regulatory, legal, fiscal, environmental, political and governmental factors; reputational factors and transaction and commercial factors. Further details on the factors that may cause actual results and other developments to differ significantly from the expectations implied or explicitly contained in this document are given in the Risk Factors section of the current ENDESA regulated information filed with the Comisión Nacional del Mercado de Valores (the Spanish securities regulator or the CNMV for its initials in Spanish). No assurance can be given that the forward-looking statements in this document will be realised. Except as may be required by applicable law, neither Endesa nor any of its affiliates intends to update these forward-looking statements. 26

endesa 1Q 2012 results

endesa 1Q 2012 results 09 05 2012 endesa 1Q 2012 results Market context in 1Q 2012 Demand consolidated results 1Q 2012 Spain: demand decrease mainly due to industry and services Spain Endesa distribution area +0.8% -1.0% -2.0%

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Consolidated: Financial Summary

Consolidated: Financial Summary FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating

More information

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

MARCH 2014 RESULTS PRESENTATION Madrid, 2014 MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

1Q 2018 consolidated results. May 9, 2018

1Q 2018 consolidated results. May 9, 2018 1Q 2018 consolidated results May 9, 2018 Highlights Ordinary EBITDA +4% driven by renewables and retail Net income increase 10% on operating dynamics and active liability management Industrial growth ~130

More information

ELICA 2012 Q3 RESULTS. November 14,

ELICA 2012 Q3 RESULTS. November 14, ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

1Q 2014 Earnings Release

1Q 2014 Earnings Release 1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Investor Presentation

Investor Presentation Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

1Q2005. Hera Group presentation

1Q2005. Hera Group presentation 1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients

More information

M e d i a s e t G r o u p

M e d i a s e t G r o u p M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

1Q 2009 Results Presentation. 12 May 2009

1Q 2009 Results Presentation. 12 May 2009 1Q 2009 Results Presentation 12 May 2009 1 Broadcasting 2 MEDIASET 2009 1Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs. 2008 +5.3% 15-64 years +5.6% 1Q TV CONSUMPTION (2000-2009) Average

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Summary Statement of Financial Position (consolidated)

Summary Statement of Financial Position (consolidated) 2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

2010 First Quarter Results Presentation. 11 th May 2010

2010 First Quarter Results Presentation. 11 th May 2010 2010 First Quarter Results Presentation 11 th May 2010 1 Broadcasting 2 ITALY TV Consumption trend (2003-2010) Average Daily minutes 271 273 270 270 Individuals 269 266 255 250 251 245 251 256 245 244

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Telekom Austria Group Results for the First Quarter May 16, 2007

Telekom Austria Group Results for the First Quarter May 16, 2007 Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

May 6, 2008 First Quarter 2008 Results

May 6, 2008 First Quarter 2008 Results SWEUB2227319CMDV7 May 6, 28 First Quarter 28 Results 1Q 28: Improved results in a challenging environment Page 2 Strong loan growth at 34.2% yoy Accelerated deposit growth at 31% yoy; improved loans /

More information

Designing a Smoke-Free Future

Designing a Smoke-Free Future Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

UE / PGE / 100 TOOMAN TINKER SCHUE BEFORE THE PUBLIC UTILITY COMMISSION OF THE STATE OF OREGON Power Costs PORTLAND GENERAL ELECTRIC COMPANY Direct Testimony and Exhibits of L. Alex Tooman- Jay Tinker

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1- BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest

More information

ESM Pricing Policy. Element of Pricing and Calculation of Interest Rate. 1. Base Rate

ESM Pricing Policy. Element of Pricing and Calculation of Interest Rate. 1. Base Rate ESM Pricing Policy Objective When granting stability support, the ESM shall aim to fully cover its financing and operating costs and shall include an appropriate margin (Art. 20 of the Treaty). The main

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

CENTRALE. Monetary. compared. domestic. million.

CENTRALE. Monetary. compared. domestic. million. CENTRALE BANK VAN ARUBAA Statistical News Release Second Quarter 2012 Date: November 7, 2012 Monetary and financial developments Money and credit In the second quarterr of 2012, the money supply decreased

More information

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish

More information

ASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012

ASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012 ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair

More information

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total

More information

The acquisition of Fortitech

The acquisition of Fortitech The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale

More information

Inflation projection of the National Bank of Poland based on the NECMOD model

Inflation projection of the National Bank of Poland based on the NECMOD model Warsaw, July 1 Inflation projection of the National Bank of Poland based on the NECMOD model Economic Institute THE JUNE AS COMPARED TO THE FEBRUARY Change in the projection scenario Re-estimation of the

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

Results Briefing. 15 ~ 17 May 2007

Results Briefing. 15 ~ 17 May 2007 Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights

More information

Company Overview February 26, 2019

Company Overview February 26, 2019 Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014

More information

Oral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development

Oral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements

More information

ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011

ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 STRUCTURE 1. National economy 2. International economy 3. Outlook 2 CENTRALE

More information

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1 Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking

More information

Operational Efficiency:

Operational Efficiency: Operational Efficiency: metrics that matter Copyright Altus Ltd 214. All rights reserved. Kevin Okell Consultancy Director 15/5/214 From distribution chain to value chain Ad-valorem pricing driven from

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007 Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS

REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage

More information

Q Investor Kit January December 2015

Q Investor Kit January December 2015 Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local

More information

First Quarter Results to March 31, Shire plc April 25, 2008

First Quarter Results to March 31, Shire plc April 25, 2008 First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical

More information

Singapore Exchange Limited 1Q FY2009 Financial Results

Singapore Exchange Limited 1Q FY2009 Financial Results Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008

More information

SWEDISH MATCH RESULTS PRESENTATION Q3 2017

SWEDISH MATCH RESULTS PRESENTATION Q3 2017 SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

Passion for progress, care for people

Passion for progress, care for people Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.

More information

TELECONFERENCE Q August 2015

TELECONFERENCE Q August 2015 TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant

More information

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr. MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its

More information

Results Briefing Junichi Yoshii President & Representative Director

Results Briefing Junichi Yoshii President & Representative Director Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

Brookings Institution, March 4, 2013 Laura Papi and IMF India Team

Brookings Institution, March 4, 2013 Laura Papi and IMF India Team Brookings Institution, March, 13 Laura Papi and IMF India Team The views expressed in this presentation are those of the authors and should not be attributed to the International Monetary Fund, its Executive

More information

1Q 2016 IFRS Financial Results. Moscow, June 6, 2016

1Q 2016 IFRS Financial Results. Moscow, June 6, 2016 1Q 2016 IFRS Financial Results Moscow, June 6, 2016 Forward-Looking Statements Certain statements in this presentation are not historical facts and are forward-looking. Examples of such forward-looking

More information

ThromboGenics Business Update H1 2018

ThromboGenics Business Update H1 2018 Press release 6 September 2018 Regulated Information ThromboGenics Business Update H1 2018 Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion

More information

Woongjin Coway. 1Q 12 IR Presentation

Woongjin Coway. 1Q 12 IR Presentation Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This

More information

CITY OF VALLEJO HIDDENBROOKE IMPROVEMENT DISTRICT NO IMPROVEMENT LEVY ADMINISTRATION REPORT FISCAL YEAR

CITY OF VALLEJO HIDDENBROOKE IMPROVEMENT DISTRICT NO IMPROVEMENT LEVY ADMINISTRATION REPORT FISCAL YEAR CITY OF VALLEJO HIDDENBROOKE IMPROVEMENT DISTRICT NO. 1998-1 IMPROVEMENT LEVY ADMINISTRATION REPORT FISCAL YEAR 2010-11 December 17, 2010 Hiddenbrooke Improvement District No. 1998-1 Improvement Levy Administration

More information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,

More information

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183) Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700

More information

The Global Economic Crisis and HIV Prevention and Treatment Programmes: Vulnerabilities and Impact. Executive Summary TRINIDAD AND TOBAGO

The Global Economic Crisis and HIV Prevention and Treatment Programmes: Vulnerabilities and Impact. Executive Summary TRINIDAD AND TOBAGO The Global Economic Crisis and HIV Prevention and Treatment Programmes: Vulnerabilities and Impact Executive Summary TRINIDAD AND TOBAGO October 2009 ACKOWLEDGEMENT The executive summary The Global Economic

More information

PATENCY-1 Top-Line Results

PATENCY-1 Top-Line Results PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,

More information

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public Incorporation of BVI Business Companies under the BVI Business Companies Act, 2004 1. Introduction The following is a brief summary of the main

More information

JEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016

JEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016 JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,

More information

MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m.

MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m. MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m. The shareholders of the company Solvay S.A. with its corporate offices in Brussels, rue de Ransbeek, no. 310,

More information

Second Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1

Second Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1 Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including

More information

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development

More information

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness

More information